Company profile
Tvardi Therapeutics, Inc.
NASDAQ: TVRD · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
35DFH 39DQ —GM 16SS 46
v0.1 · 45/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$18.2M
Employees
12
as of 2026-08-21
Market cap
$17.2M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$18.2M-$18.2M2025
Operating income-$26.7M-$26.7M2025
Total assets$32.1M$32.1M2025
Liabilities$11.1M$11.1M2025
Equity$20.9M$20.9M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Tvardi Therapeutics, Inc.’s revenue?
Tvardi Therapeutics, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Rein Therapeutics Inc.36DOcumetics Technology Corp.——KALA BIO, Inc.30DPalatin Technologies, Inc.40DInhibitor Therapeutics, Inc.29DBiomind Labs Inc.——Neighbors
Fort Bend →Key facts
CEOImran Alibhai
SectorHealthcare
IndustryBiotechnology
HeadquartersSugar Land, TX
ExchangeNASDAQ: TVRD
Employees12
IPO date2014-01-31
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.